Abstract
We treated 34 chemotherapy-naive patients with stage IIIb or IV non-small cell lung cancer with trimetrexate 150-200 mg/m2 intravenously over 30 minutes every two weeks. Six of 31 evaluable patients (19%) achieved a partial response. The major toxic effects from this regimen were myelosuppression, nausea/vomiting, and skin rash. We conclude that this well-tolerated schedule of trimetrexate has significant activity as a single agent against non-small cell lung cancer.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Multicenter Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Carcinoma, Bronchogenic / drug therapy*
-
Carcinoma, Bronchogenic / secondary
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / secondary
-
Drug Administration Schedule
-
Female
-
Humans
-
Infusions, Intravenous
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Trimetrexate / administration & dosage
-
Trimetrexate / adverse effects
-
Trimetrexate / therapeutic use*